梅州阴道炎怎么彻底治疗梅州市哪家医院做无痛人流,梅州割双眼皮要多少钱啊,梅州慢性附件炎的医治方法,梅州衣原体阴道炎治疗,梅州做完人流多长时间可以带环,梅州做流产都有哪些大医院,梅州人流一共要多少钱

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

WASHINGTON, Jan. 20 (Xinhua) -- Visiting Chinese President Hu Jintao on Thursday called upon the U.S. Congress to continue helping the two countries boost their relations.Pursuing a healthy and steady development of China-U.S. ties is China's established policy and strategic choice, Hu stressed in talks here with Speaker John Boehner of the House and Majority leader Harry Reid of the Senate.It has also been the consensus of the U.S. administrations, whether Republican or Democratic, since the two countries established formal diplomatic relations 32 years ago, he added.Chinese President Hu Jintao (2nd L front) meets with U.S. Senate Majority Leader Harry Reid (2nd R front) on Capitol Hill in Washington, the United States, Jan. 20, 2011Thanks to the two nations' concerted efforts, the China-U.S. relationship has been moving forward steadily, Hu said, citing the two countries' increasing cooperation and coordination on trade, terrorism, climate change, Korean Peninsula denuclearization and other bilateral, regional and global issues.A sound relationship between Beijing and Washington not only serves the fundamental interests of both peoples, but greatly contributes to the peace, stability and prosperity of the Asia-Pacific region and beyond, the Chinese president said.With China and the United States differing in culture, social system and development level, it is normal for the two sides to have differences on some issues, he said.But what matters most is the common interests of the two countries, he stressed, saying that Beijing's position is that the two sides should seek common ground while reserving differences, so as to learn from each other and pursue common prosperity on the basis of mutual respect and equality.

BEIJING, March 17 (Xinhuanet) -- A new study has shown that gene therapy can reduce symptoms in patients with Parkinson's, media reports said Thursday.The study, published in the journal Lancet Neurology, is the first to show positive results in a test of gene therapy against a sham operation in 45 U.S. Parkinson's patients.The treated group showed a 23.1 percent improvement on a scale of Parkinson's symptoms six months after treatment, compared to a 12.7 percent improvement for patients who received sham surgery, according to the published research."Gene therapy is no longer just a theory," said Michael Kaplitt, a neurosurgeon at New York-Presbyterian Hospital and Weill Cornell Medical Center, and one of the study authors. "We are getting much closer to a reality where this treatment can be offered to patients."In patients with Parkinson's disease, their brains get overactive after losing the normal supply of a chemical called GABA. The new treatment, gene therapy, works by inserting billions of copies of a gene into patients' brains that helps them produce more GABA.Kaplitt said the results might spur similar treatments for other brain disorders like Alzheimer's, epilepsy and depression.

BEIJING, Jan. 26 (Xinhua) -- A senior Chinese official has called on the country's judicial officers and other law enforcers to maintain social justice and harmony by defusing and solving social contradictions.Zhou Yongkang, a member of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee, made the remark at a meeting to call on law enforcement officials to learn from Liu Yumei, who had served in grassroots judicial work for more than 20 years.During her service in a local community in southwest Chongqing Municipality, Liu Yumei had successfully reconciled more than 1,500 civil disputes and defused more than 10 possibly violent events. Liu died of illness from overwork in Jan. 2010 at only 46 years old.Zhou said law enforcement organs should regard preventing and reducing social disputes as an important job, and judicial officers should help people with their problems during their law-enforcement practices.

LOS ANGELES, May 25 (Xinhua) -- NASA project managers bade farewell to the Mars rover Spirit on Wednesday after sending a final set of commands to the stranded vehicle.This marks the completion of one of the most successful missions of interplanetary exploration ever launched, NASA's Jet Propulsion Laboratory (JPL) said."Last night, just after midnight, the last recovery command was sent to Spirit," said John Callas, the Mars Exploration Rover Project manager at NASA's Jet Propulsion Laboratory (JPL) in Pasadena, Los Angeles."It would be an understatement to say this was a significant moment. Since the last communication from Spirit on March 22, 2010, as she entered her fourth Martian winter, nothing has been heard from her."NASA has tried in vain to regain communication with Spirit since it got stuck in sand about two years ago. The rover last communicated on March 22, 2010, as Martian winter approached and the rover's solar-energy supply declined.NASA checked frequently in recent months for possible reawakening of Spirit as solar energy available to the rover increased during Martian spring, but to no avail.A series of additional re-contact attempts ended on Wednesday, designed for various possible combinations of recoverable conditions, according to JPL."Our job was to wear these rovers out exploring, to leave no unutilized capability on the surface of Mars, and for Spirit, we have done that," said Callas.